Immix Biopharma, Inc. financial data

Symbol
IMMX on Nasdaq
Industry
Pharmaceutical Preparations
Location
11400 West Olympic Blvd., Suite 200, Los Angeles, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 25, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 416 % -38.7%
Debt-to-equity 35 % +106%
Return On Equity -105 % -3.41%
Return On Assets -77.7 % +10.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 27.7M shares +5.02%
Common Stock, Shares, Outstanding 27.5M shares +38.2%
Entity Public Float 32.4M USD +16%
Common Stock, Value, Issued 2.76K USD +38.1%
Weighted Average Number of Shares Outstanding, Basic 28.3M shares +63.1%
Weighted Average Number of Shares Outstanding, Diluted 28.3M shares +63.1%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 11.3M USD +29.3%
General and Administrative Expense 11.4M USD +53.7%
Operating Income (Loss) -22.7M USD -40.5%
Nonoperating Income (Expense) 1.02M USD +77.9%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -21.7M USD -39.1%
Income Tax Expense (Benefit) 41K USD +55.4%
Net Income (Loss) Attributable to Parent -21.6M USD -40.1%
Earnings Per Share, Basic -0.76 USD/shares +14.6%
Earnings Per Share, Diluted -0.76 USD/shares +14.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 17.7M USD +0.98%
Other Assets, Current 32.3K USD -27.6%
Assets, Current 20.2M USD +2.07%
Property, Plant and Equipment, Net 1.74M USD +3368%
Operating Lease, Right-of-Use Asset 989K USD
Other Assets, Noncurrent 20.4K USD
Assets 22.9M USD +15.2%
Accounts Payable, Current 5.39M USD +276%
Employee-related Liabilities, Current 658K USD +13.9%
Liabilities, Current 8.69M USD +133%
Operating Lease, Liability, Noncurrent 1.01M USD
Liabilities 9.7M USD +161%
Accumulated Other Comprehensive Income (Loss), Net of Tax -1.06K USD -101%
Retained Earnings (Accumulated Deficit) -75M USD -40.5%
Stockholders' Equity Attributable to Parent 13.3M USD -19.2%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 13.3M USD -18.2%
Liabilities and Equity 22.9M USD +15.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.83M USD -82.9%
Net Cash Provided by (Used in) Financing Activities 15.9M USD +13312%
Net Cash Provided by (Used in) Investing Activities -302K USD
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 27.6M shares +38.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 11.8M USD
Deferred Tax Assets, Valuation Allowance 15.8M USD +107%
Operating Lease, Liability 1.07M USD
Depreciation 3.01K USD +496%
Payments to Acquire Property, Plant, and Equipment 302K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -21.7M USD -41.4%
Lessee, Operating Lease, Liability, to be Paid 1.53M USD
Property, Plant and Equipment, Gross 64.5K USD 0%
Operating Lease, Liability, Current 65.2K USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 153K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 148K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 458K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 158K USD
Deferred Tax Assets, Operating Loss Carryforwards 6.71M USD +64.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 164K USD
Additional Paid in Capital 88.4M USD +26.6%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 590K USD +167%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%